Core Viewpoint - The IPO application of Zhuhai Tainomai Bo Pharmaceutical Co., Ltd. has been accepted, marking it as the first company to utilize the fifth set of standards for the Sci-Tech Innovation Board since its restart on June 18, 2025 [2][5]. Group 1: IPO Details - Tainomai Bo's IPO application was accepted on July 31, 2025, with Huatai Securities as the sponsor [2][3]. - The company plans to raise 1.5 billion RMB for new drug research and development, expansion of antibody production facilities, and to supplement working capital [12][13]. Group 2: Company Background - Tainomai Bo is an innovative biopharmaceutical company focused on global markets, specializing in blood product alternatives [8]. - The company has developed the "First-in-Class" Staitouta monoclonal antibody injection, recognized as a breakthrough treatment drug in the anti-infection field [9]. Group 3: Financial Performance - The company reported minimal revenue, with the Staitouta monoclonal antibody injection expected to generate sales starting in March 2025 [9]. - Tainomai Bo has incurred continuous net losses, with cumulative losses reaching 1.024 billion RMB by the end of the reporting period [11].
科创板第五套上市标准重启后,首家受理企业来了!
中国基金报·2025-08-01 06:28